COVID-19 Pandemi Döneminde Altmış Beş Yaş Üstü Neovasküler Glokomlu Bireylerin Prevalansındaki Değişiklikler

Amaç: Pandeminin farklı dönemlerinde 3. basamak bir hastaneye başvuran 65 yaş üstü neovasküler glokomlu olguların sayısında, GİB’ ı ve görme düzeylerindeki değişikliği incelemeyi amaçlamaktadır. Materyal ve metod: Hastalar karantina öncesi (21 mart 2019 -10 haziran 2019), karantina dönemi (21 mart 2020 -10 haziran 2020), karantina sonrası (21 mart 2021 -10 haziran 2021) 65 yaş üstü neovasküler glokom tanılı hastalar olmak üzere 3 gruba ayrıldı. Yaş, cinsiyet, dahil olan göz(ler), etiyoloji, göz içi basıncı (GİB), en iyi düzeltilmiş görme keskinliği (EİDGK), uygulanan tedaviler karşılaştırıldı. Bulgular: Karantina öncesi gruba göre karantina grubunda % 51.02, karantina sonrası grubunda % 14.29 oranında hasta sayısında azalma tespit ettik. Karantina döneminde uygulanan tedavi sayısı, karantina öncesi döneme göre % 51.85 azaldı (p=0.002). Karantina ve karantina sonrası dönem, karantina öncesi ile karşılaştırıldığında ortalama EİDGK seviyelerinde istatiksel anlamlı fark saptanmadı (p=0.078). Ancak ortalama GİB değerlerinde anlamlı fark tespit edildi (p<0.001) Sonuç: 65 yaş üstü neovasküler glokomlu hastaların karantina sürecinde ve sonrasında hastaneye başvurularında azalma tespit edildi. Karantina sürecinden sonra tedavinin gecikmesine bağlı olarak görme düzeylerinde azalma, GİB seviyelerinde yükselme mevcut idi. İlerleyen dönemlerde kaçınılmaz olarak neovasküler glokomlu hasta ve cerrahi sayısında artış görülecektir.

Anahtar Kelimeler:

COVID-19, geriatri, göz içi basıncı, neovasküler glokom, görme keskinliği

Changes in the Prevalence of Neovascular Glaucoma in Individuals Over Sixty-Five Years of Age During the Covid-19 Pandemic

Keywords:

göz içi basıncı, neovasküler glokom, görme keskinliği, COVID-19, geriatri,

PDF

___

1. Aki OE. COVID-19 pandemic and the mental health of el-derly. Turkish Journal of Geriatrics, 2020; 23(3): 291-8. (DOI: 10.31086/tjgeri.2020.165)
2. Ahmed I, Liu TYA. The ımpact of COVID-19 on diabetic reti-nopathy monitoring and treatment. Curr Diab Rep. 2021;21(10): 40. (PMID: 34495377)
3. Karslıoğlu MZ, Öztürkmen C, Kesim C, Taş AY, Günel Kara-deniz P, Şahin A. Survey of the ımpact of the COVID-19 pandemic on ophthalmology clinical practice in Turkey. Turk J Ophthalmol. 2021;51(5):269-81. (PMID: 34702020)
4. Kodjikian L. Quelle conduite à tenir adopter vis à vis des injections intravitréennes (IVT) dans cette période d’épidémie au Covid-19 – SARS-CoV-2 ? [How to approach intravitreal injections during this COVID-19 pandemic ?]. J Fr Ophtalmol. 2020;43(6): 539-40. (PMID: 32451137)
5. Sindal MD, Chhabra K, Khanna V. Profile of patients recei-ving intravitreal anti-vascular endothelial growth factor in-jections during COVID-19-related lockdown. Indian J Opht-halmol. 2021; 69(3): 730-3. (PMID: 33595512)
6. Vancea PP, Abu-Taleb A. Actualităţi in tratamentul glauco-mului neovascular [Current trends in neovascular glauco-ma treatment]. Rev Med Chir Soc Med Nat Iasi. 2005; 109(2): 264-8. (PMID: 16607783)
7. Bulut MN, Sönmez HS, Gökçe G, Ağaçkesen A, Bulut K, Hacısalihoğlu A, et al. The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown. Photodiagnosis Photodyn Ther. 2021; 35: 102449. (PMID: 34314862)
8. Medert CM, Sun CQ, Vanner E, Parrish RK 2nd, Wellik SR. The influence of etiology on surgical outcomes in neovas-cular glaucoma. BMC Ophthalmol. 2021; 21(1): 440. (PMID: 34930191)
9. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001; 108(10): 1767-76. (PMID: 11581047)
10. Yang W, Kandula S, Huynh M, Greene SK, Van Wye G, Li W, et al. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis. Lancet Infect Dis. 2021; 21(2):203-12. (PMID: 33091374)
11. CDC COVID-19 Response Team. Severe outcomes among patients with Coronavirus Disease 2019 (COVID-19) - Uni-ted States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(12): 343-6. (PMID: 32214079)
12. Weng CC, Lin TY, Yang YP, Hsiao YJ, Lin TW, Lai WY, et al. Modifications of intravitreal injections in response to the COVID-19 pandemic. J Chin Med Assoc. 2021; 84(9): 827-32. (PMID: 34292208)
13. Korobelnik JF, Loewenstein A, Eldem B, Joussen AM, Koh A, Lambrou GN, et al. Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epi-demic pressure. Graefes Arch Clin Exp Ophthalmol. 2021; 259(3): 567-74. (PMID: 33528647)
14. El Hamichi S, Gold A, Heier J, Kiss S, Murray TG. Impact of the COVID-19 pandemic on essential vitreoretinal care with three epicenters in the United States. Clin Ophthal-mol. 2020; 14: 2593-8. (PMID: 32982151)
15. Carnevali A, Giannaccare G, Gatti V, Scuteri G, Randazzo G, Scorcia V. Intravitreal injections during COVID-19 outbreak: Real-world experience from an Italian tertiary referral cen-ter. Eur J Ophthalmol. 2021; 31(1): 10-2. (PMID: 32967465)
16. Posarelli C, Maglionico MN, Covello G, Loiudice P, Cipriano A, Santini M, et al. Ophthalmological emergencies and the SARS-CoV-2 outbreak. PLoS One. 2020; 15(10): e0239796. (PMID: 33002074)
17. Rajendrababu S, Durai I, Mani I, Ramasamy KS, Shukla AG, Robin AL. Urgent and emergent glaucoma care during the COVID-19 pandemic: An analysis at a tertiary care hospital in South India. Indian J Ophthalmol. 2021; 69(8): 2215-21. (PMID: 34304213)
18. Maalej R, Hage R, Salviat F, Vignal-Clermont C. Impact of lockdown during the COVID-19 outbreak on ophthalmolo-gical emergencies in a referral center in France. J Fr Oph-talmol. 2022; 45(1): 1-8. (PMID: 34823891)
19. Billioti de Gage S, Drouin J, Desplas D, Cuenot F, Dray-Spira R, Weill A, et al. Intravitreal anti-vascular endothelial growth factor use in France during the Coronavirus Disease 2019 pandemic. JAMA Ophthalmol. 2021; 139(2): 240-2. (PMID: 33331873)
20. Yang KB, Feng H, Zhang H. Effects of the COVID-19 pande-mic on anti-vascular endothelial growth factor treatment in China. Front Med (Lausanne). 2020; 7: 576275. (PMID: 33381511)
21. Stone LG, Grinton ME, Talks JS. Delayed follow-up of me-dical retina patients due to COVID-19: Impact on disease activity and visual acuity. Graefes Arch Clin Exp Ophthal-mol. 2021; 259(7): 1773-80. (PMID: 33977317)
22. Naravane AV, Mundae R, Zhou Y, Santilli C, van Kuijk FJGM, Nazari H, et al. Short term visual and structural out-comes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study. PLoS One. 2021; 16(2): e0247161. (PMID: 33596257)
23. Quaranta L, Micheletti E, Riva I. Glaucoma surgery during the COVID-19 pandemic in Italy: How novel coronavirus has changed the surgical management of glaucoma pati-ents. J Glaucoma. 2020; 29(10): 831-2. (PMID: 32852378)
24. Krishna U, Venkatesh R, Srinivasan K, Odayappan A, Robin AL. Letter to the Editor: Glaucoma surgery during the COVID-19 pandemic in Italy: How novel coronavirus has changed the surgical management of glaucoma patients. J Glaucoma. 2021; 30(4): e187-8. (PMID: 33596012)
25. dell'Omo R, Filippelli M, Virgili G, Bandello F, Querques G, Lanzetta P, et al. Eyecare in Italy during COVID-19 pande-mic (EICO) study group. Effect of COVID-19-related lock-down on ophthalmic practice in Italy: A report from 39 ins-titutional centers. Eur J Ophthalmol. 2022; 32(1): 695-703. (PMID: 33724078).